Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Sponsors
- Children's Hospital of Philadelphia
- Collaborators
- Bayer
- Tags
- Tyrosine Kinase (TK) Inhibitor, Radiation Therapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1771
- NCT Identifier
- NCT05783323
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.